AtriCure, Inc. (ATRC)

NGM – Real Time Price. Currency in USD

43.11

+0.16 (0.37%)

Market open: Aug 12, 2026, 2:06 PM EDT

43.33

+0.38 (0.89%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

12.08.2026

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

AtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.

07.08.2026

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

This disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.

07.08.2026

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Karen Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.

Videos

No Data

There is no data to display

AtriCure, Inc. (ATRC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AtriCure, Inc. (ATRC)

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videos

No Data

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videos

No Data

Search stocks

AtriCure, Inc. (ATRC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AtriCure, Inc. (ATRC)

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videos

No Data

AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors

An AtriCure Director Sold $905,000 in Stock. Here's How to Read It

Videos

No Data